{
    "clinical_study": {
        "@rank": "21753", 
        "arm_group": [
            {
                "arm_group_label": "KTP-001 (First Cohort; Low Dose)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "KTP-001 (Second Cohort; Lower Middle Dose)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "KTP-001 (Third Cohort; Higher Middle Dose)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "KTP-001 (Fourth Cohort; High Dose)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and exploratory efficacy of KTP-001 in\n      subjects with lumbar disc herniation."
        }, 
        "brief_title": "A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation", 
        "condition": "Lumbar Disc Herniation", 
        "condition_browse": {
            "mesh_term": [
                "Hernia", 
                "Intervertebral Disk Displacement"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has had a single contained or noncontained (extruded) lumbar disc herniation\n             (L3-L4, L4-L5 or L5-S1) diagnosed by clinical symptoms and/or physical findings and\n             confirmed by MRI.\n\n          -  Subject has leg pain with a documented positive straight leg raise (SLR) test or\n             femoral stretch test (FST).\n\n          -  Subject has experiences herniated disc symptoms for at least 6 weeks prior to the\n             study without relief with pain medications and other therapies.\n\n          -  Subject has a BMI of 18 to 35 kg/m2\n\n        Exclusion Criteria:\n\n          -  Subject has a sequestered lumbar disc herniation or intrathecal herniation confirmed\n             by MRI\n\n          -  Subject has two or more symptomatic lumbar disc herniations\n\n          -  Previous intradiscal therapeutic intervention or has had any lumbar surgery\n\n          -  Presence of lumbar spine disease and/or deformity other than a lumbar disc herniation\n\n          -  Active smoker or is unable to abstain from tobacco use for 2 weeks prior to study\n             injection\n\n          -  Subject has a history or presence of significant cardiovascular, pulmonary, hepatic,\n             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,\n             neurologic, or psychiatric disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978912", 
            "org_study_id": "KTP-001-CL-101"
        }, 
        "intervention": {
            "arm_group_label": [
                "KTP-001 (First Cohort; Low Dose)", 
                "KTP-001 (Second Cohort; Lower Middle Dose)", 
                "KTP-001 (Third Cohort; Higher Middle Dose)", 
                "KTP-001 (Fourth Cohort; High Dose)"
            ], 
            "description": "KTP-001 is one time dose intradiscally.", 
            "intervention_name": "KTP-001", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Encinitas", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Royal Oak", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation", 
        "other_outcome": [
            {
                "measure": "Lower back pain or leg pain", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Spinal flexion/tension", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Oswestry disability index (ODI)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Short form-12 (SF-12)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Patient global impression of change (PGI-C)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "overall_contact": {
            "email": "michael.beblavy@iconplc.com", 
            "last_name": "Michael Beblavy", 
            "phone": "215-616-3243"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety assessed by Adverse events, Magnetic resonance imaging (MRI), X-ray Imaging, Physical examination, Neurologic examination and Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Safety assessed by 12-lead electrocardiogram (ECG) and Clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "13 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978912"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum concentrations of KTP-001", 
                "safety_issue": "Yes", 
                "time_frame": "13 weeks"
            }, 
            {
                "measure": "Anti-KTP-001 antibody", 
                "safety_issue": "Yes", 
                "time_frame": "13 weeks"
            }
        ], 
        "source": "Teijin America, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Teijin America, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}